Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 3
2018 2
2019 6
2020 7
2021 13
2022 13
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Vellano CP, et al. Among authors: pagan e. Nature. 2022 Jun;606(7915):797-803. doi: 10.1038/s41586-022-04833-8. Epub 2022 Jun 15. Nature. 2022. PMID: 35705814 Free PMC article.
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD. Conforti F, et al. Among authors: pagan e. BMJ. 2021 Dec 21;375:e066381. doi: 10.1136/bmj-2021-066381. BMJ. 2021. PMID: 34933868 Free PMC article.
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Vellano CP, et al. Among authors: pagan e. Nature. 2023 Jan;613(7945):E3. doi: 10.1038/s41586-022-05632-x. Nature. 2023. PMID: 36627494 No abstract available.
Different Response to Immunotherapy According to Melanoma Histologic Subtype.
Pala L, Conforti F, Pagan E, Bagnardi V, De Pas TM, Mazzarol G, Barberis M, Pennacchioli E, Orsolini G, Prestianni P, Zagami P, Nicolo' E, Patanè D, Saponara M, Queirolo P. Pala L, et al. Among authors: pagan e. J Immunother. 2022 Feb-Mar 01;45(2):119-124. doi: 10.1097/CJI.0000000000000403. J Immunother. 2022. PMID: 34908006
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials.
Pala L, De Pas T, Pagan E, Sala I, Catania C, Zattarin E, Arnone P, Grassi MM, Colleoni M, Wolff AC, Cortes J, Piccart M, Gelber RD, Viale G, Bagnardi V, Conforti F. Pala L, et al. Among authors: pagan e. Breast. 2023 Jun;69:258-264. doi: 10.1016/j.breast.2023.02.012. Epub 2023 Mar 2. Breast. 2023. PMID: 36898259 Free PMC article.
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L, De Pas T, Pagan E, Minucci S, Catania C, Digiacomo N, Cocorocchio E, Laszlo D, Di Muzio A, Barigazzi C, Stucchi E, De Grandi L, Stucchi S, Viale G, Gelber RD, Bagnardi V, Conforti F. Pala L, et al. Among authors: pagan e. Semin Oncol. 2023 Feb-Apr;50(1-2):34-39. doi: 10.1053/j.seminoncol.2023.03.003. Epub 2023 Mar 21. Semin Oncol. 2023. PMID: 36967333 Review.
Ten-year outcome results of cT4 breast cancer after neoadjuvant treatment.
Corso G, Kahler-Ribeiro-Fontana S, Pagan E, Bagnardi V, Magnoni F, Munzone E, Bottiglieri L, Veronesi P, Galimberti V. Corso G, et al. Among authors: pagan e. J Surg Oncol. 2021 Dec;124(8):1242-1250. doi: 10.1002/jso.26662. Epub 2021 Sep 1. J Surg Oncol. 2021. PMID: 34472105
45 results